COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur
- Conditions
- Volunteers From the Institute Curie and Institute Pasteur Staff Who Are Not Showing Active SARS-CoV-2 Infection
- Interventions
- Diagnostic Test: Blood samples (collection of 5 mL of blood in a dry tube)Diagnostic Test: Nasopharyngeal swabs
- Registration Number
- NCT04369066
- Lead Sponsor
- Institut Curie
- Brief Summary
This research proposes to study a large healthy population active for the presence of antibodies directed against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus and this over time.
After verification of the inclusion criteria and information by the coordinating investigative doctor, the volunteers sign a written consent. A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data.
The blood samples will be taken at 4 times for Institute Curie and Institute Pasteur: T0 (day of inclusion), between 6 weeks and 3 months ,6 months and 12 months post-inclusion.
Each blood sample consists of a collection of 5 mL of blood in a dry tube. The serum samples will be extracted and collected prospectively from the blood samples.
The nasopharyngeal swabs will be performed at 3 times: , between 6 weeks and 3 months, 6 months and 12 months post-inclusion for Institute Curie staff who have had at least one of the following four criteria on the sample or questionnaire carried out at T0:
* have had RT-PCR+
* and/or presence of antibodies at the 95% threshold
* and/or anosmia/ageusia
* and/or digestive syndrome with associated respiratory signs. In case of infection between sampling times, if the volunteer meets one of the four criteria above, a nasopharyngeal swab will be performed during the following visits.
The nasopharyngeal swab shall also be proposed to volunteers not meeting the 4 above listed criteria in order to have a control group (about 100 volunteers) for future statistical analyses.
If the volunteers accept, naso-pharyngeal swab shall be performed between 6 weeks and 3 months, 6 months and 12 months after inclusion.
For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) between 2 sampling times already planned in the flow chart, blood samples and nasopharyngeal swabs shall be performed.
Those shall be performed if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.
The blood samplings and nasopharyngeal swabs will be performed at 4 times for Institute Pasteur personnel: at T0 (inclusion day), between 6 weeks and 3 months, at 6 months and 12 months post-inclusion
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1971
- Person, adult volunteer outside of any acute infectious episode with SARS-CoV-2* (see paragraph indication), working at the Institute Curie and able to exercise their professional activity on one of the 3 sites of the Institute Curie: Paris, Orsay or Saint Cloud, or on the Campus of the Institute Pasteur.
- Person aged 18 or over.
- Information and consent of the person to the procedures related to the study (cf. information note / consent).
From November 2020, person having presented at least one of the following criteria since January 2020:
- A positive diagnostic test for SARS-COV-2 by PCR on a nasopharyngeal sample or antigenic test,
- A positive SARS-CoV-2 serology,
- An anosmia or / and an ageusia,
- A respiratory infection ** associated with digestive signs **
whatever the working methods during confinement * Subjects who are not showing active SARS-CoV-2 infection are considered volunteers at the time of inclusion: people with no clinical signs ** suggestive of SARS-CoV-2 infection at the time of collection or having had an end of symptoms for more than 7 days [1].
** fever, fatigue, cough, shortness of breath, difficulty to breath, loss of taste or smell, headache, body aches, conjunctivitis or cold, digestive problems (vomiting, diarrhea), whether or not the signs led to sick leave, treatment and / or hospitalization [2].
- Declaration by the subject of signs suggestive of Coronavirus Infectious Disease 2019 (COVID-19) infection with SARS-CoV-2 in progress or for which the end of symptoms dates from less than 7 days
- Inability to submit to study monitoring for geographic, social or psychological reasons
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Subjects who are not showing active SARS-Cov2 infection Blood samples (collection of 5 mL of blood in a dry tube) - Subjects who are not showing active SARS-Cov2 infection Nasopharyngeal swabs -
- Primary Outcome Measures
Name Time Method Antibodies against the SARS-CoV-2 virus in serum at inclusion 1 day Detection of antibodies against the SARS-CoV-2 virus with serological tests
Antibodies against the SARS-CoV-2 virus in serum at 1 month 1 month Detection of antibodies against the SARS-CoV-2 virus with serological tests
Antibodies against the SARS-CoV-2 virus in serum at 3 months 3 months Detection of antibodies against the SARS-CoV-2 virus with serological tests
Antibodies against the SARS-CoV-2 virus in serum at 6 months 6 months Detection of antibodies against the SARS-CoV-2 virus with serological tests
Antibodies against the SARS-CoV-2 virus in serum at 12 months 12 months Detection of antibodies against the SARS-CoV-2 virus with serological tests
- Secondary Outcome Measures
Name Time Method Prevalence of immune subjects for SARS-CoV-2 3 months Prevalence of immune subjects for SARS-CoV-2 in a well-defined active healthy population, working at the hospital or not, leading to variable exposure levels
Comparative performance of anti-SARS-CoV-2 antibody detection techniques 9 months Comparative performance of anti-SARS-CoV-2 antibody detection techniques (sensitivity and specificity of serological tests)
Nature and quantity of anti-SARS-CoV-2 antibodies 3 months Nature and quantity of anti-SARS-CoV-2 antibodies: ImmunoglobulinM, ImmunoglobulinG and ImmunoglobulinA)
Evolution of the different antibodies against the SARS-CoV-2 virus over time. 6 months The analysis of the evolution of serology results over time will be done by a mixed model taking into account the repeated framework of the data of a subject
Prevalence of Anti-covid IgA response in the nasal mucosa 6 months Prevalence of Anti-covid IgA in volonteers RT/PCR+ and/or presence of antibodies at the 95 % threshold and/or COVID symptoms
Trial Locations
- Locations (2)
Institut Curie
🇫🇷Paris, France
Institut Pasteur
🇫🇷Paris, France